Trends in Potent Drug Contract Manufacturing

 

Almost fifty percent of high potency medicines are in injectable form. Semi-solid drugs come next. Due to increasing and high regulatory compliance, many companies with a few drugs in their manufacturing pipeline are searching for capable contract manufacturing organizations to fix these challenges. 

This blog centers on challenges that are being faced by the market with regards to the regional distribution of providers, supply, and how the increasing demand for highly potent drugs is affecting the market in terms of mergers and acquisitions, investing/upgrading in new capital, new facilities, capacity expansion, etc. Continue reading to learn more.

The Challenge 

High potent drug contract manufacturing is one of the major revenue-generating segments in the pharmaceutical industry. There is a high demand for high-potency drugs such as IV fluids and ADCs. On the other hand, buyers are searching for high-capacity suppliers with lyophilization proficiency in the form of injectable dosage, can meet their active pharmaceutical ingredients OEL limits, and have experience handling high-potency drugs.

The challenge is on the side of supply. There are not enough number of contract manufacturing organizations that meet the exact needs of buyers. Producing high potent drugs requires appropriate containment facility, contemporary technology, and technical expertise.

This translates into pricey capital and results in high costs of operation, causing the manufacturing process expensive. This is why fewer contract manufacturing organizations are available to meet pharma KPIs.

Trends 

In recent years, contract manufacturing organizations of highly potent medicines have invested in high potency drug production proficiencies. So also, high potent API manufacturers have increased their ability to meet the demand.

Presently there is no congestion in the market, yet investment is required from suppliers to meet the expected rising demand of big pharma companies. The general high potency active pharmaceutical ingredient drugs market is expected to experience solid growth because of the patent expirations.

There is also an increasing trend of pharmaceutical companies engaging with a partner who can provide high potency active pharmaceutical ingredient manufacturing and development services. This will help to limit the overall drug development cost and time.

Does the Market Have Sufficient Supply?

The high potency industry is expanding at a very fast rate. Lately, there has been a rising request for injectable highly potent medicines. This demand is greater than the ability of the contract manufacturing organizations. This need is chiefly for lyophilized products. A major constraint in the market is the need for specific containment facilities to handle high-potency drugs.

For all your potent drug contract manufacturing needs, contact Abbvie today.

It is essential to introduce the product inside the facilities during the next 3 to 5 years. This is because once the product is within the CDMO, it is hard to move to another CDMO. This is why suppliers having both manufacturing and development at the same location delivers a competitive benefit.

In addition, pharmaceutical companies prefer to partner with a well-integrated CDMO service provider proficient at high potent active pharmaceutical ingredient development from formulation to manufacturing. Today, there are an insufficient number of CDMOs who provide both Highly Potent Active Pharmaceutical Ingredients DP and DS.

At AbbVie, we are the leading CDMO in highly potent drugs. Contact us today for your potent drug contract manufacturing solutions today.